Cox regression analysis of PFS from start of consolidation therapy in subgroups of patients with poor prognosis
| Subgroup . | VTD . | TD . | Hazard ratio . | 95% CI . | P* . |
|---|---|---|---|---|---|
| t(4;14) and/or del(17p) positive | 38 | 38 | 0.37 | 0.19-0.70 | .002 |
| del(13q) positive** | 71 | 63 | 0.48 | 0.29-0.81 | .006 |
| LDH > 190 U/L | 137 | 144 | 0.59 | 0.40-0.86 | .007 |
| β2-microglobulin > 3.5 mg/L | 59 | 67 | 0.56 | 0.34-0.92 | .022 |
| ISS stage 2-3 | 80 | 86 | 0.58 | 0.36-0.93 | .023 |
| Subgroup . | VTD . | TD . | Hazard ratio . | 95% CI . | P* . |
|---|---|---|---|---|---|
| t(4;14) and/or del(17p) positive | 38 | 38 | 0.37 | 0.19-0.70 | .002 |
| del(13q) positive** | 71 | 63 | 0.48 | 0.29-0.81 | .006 |
| LDH > 190 U/L | 137 | 144 | 0.59 | 0.40-0.86 | .007 |
| β2-microglobulin > 3.5 mg/L | 59 | 67 | 0.56 | 0.34-0.92 | .022 |
| ISS stage 2-3 | 80 | 86 | 0.58 | 0.36-0.93 | .023 |
VTD indicates bortezomib with thalidomide plus dexamethasone; TD, thalidomide plus dexamethasone; LDH, lactate dehydrogenase; and ISS, international staging system.
Wald χ2 test; hazard ratios, 95% CIs, and P values refer to the treatment effects in the stated subgroups.
Regardless of absence or presence of t(4;14) and/or del(17p).